دورية أكاديمية
Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.
| العنوان: | Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil. |
|---|---|
| المؤلفون: | Campbell L; King's College Hospital NHS Foundation Trust.; King's College London., Barbini B; King's College Hospital NHS Foundation Trust.; King's College London., Cromarty B; UK Community Advisory Board., Hamzah L; St George's Healthcare NHS Trust, London., Williams D; Brighton and Sussex University Hospitals, Brighton., Winston A; Imperial College Healthcare NHS Trust.; Imperial College, London, UK., Post FA; King's College Hospital NHS Foundation Trust.; King's College London. |
| مؤلفون مشاركون: | FANTA trial team |
| المصدر: | AIDS (London, England) [AIDS] 2024 Jul 15; Vol. 38 (9), pp. 1442-1445. Date of Electronic Publication: 2024 Jun 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : London, England : Lippincott Williams & Wilkins Original Publication: London : Gower Academic Journals, c1987- |
| مواضيع طبية MeSH: | Tenofovir*/adverse effects , Tenofovir*/therapeutic use , Tenofovir*/analogs & derivatives , Alanine*/adverse effects , Alanine*/therapeutic use , Anti-HIV Agents*/adverse effects , Anti-HIV Agents*/therapeutic use , HIV Infections*/drug therapy , HIV Infections*/complications , Adenine*/analogs & derivatives , Adenine*/adverse effects , Adenine*/therapeutic use , Fanconi Syndrome*/chemically induced, Humans ; Male ; Female ; Adult ; Middle Aged |
| مستخلص: | Twenty-eight individuals who experienced proximal renal tubulopathy (PRT, Fanconi syndrome) while receiving tenofovir disoproxil initiated tenofovir alafenamide (TAF) and were followed for 5 years. None developed recurrent PRT or experienced significant changes in estimated glomerular filtration rate (by creatinine or cystatin-C), albuminuria, proteinuria, retinol-binding proteinuria, fractional excretion of phosphate, alkaline phosphatase, or bone mineral density at the lumbar spine. These data suggest that TAF is a well tolerated treatment option for individuals vulnerable to developing PRT. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482–487. Pearson A, Haenni D, Bouitbir J, Hunt M, Payne BAI, Sachdeva A, et al. Integration of high-throughput imaging and multiparametric metabolic profiling reveals a mitochondrial mechanism of tenofovir toxicity. Function (Oxf) 2023; 4:zqac065. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867–875. Hamzah L, Jose S, Booth JW, Hegazi A, Rayment M, Bailey A, et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J Infect 2017; 74:492–500. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283–290. Hamzah L, Booth JW, Jose S, McAdoo SP, Kumar EA, O’Donnell P, et al. Renal tubular disease in the era of combination antiretroviral therapy. AIDS 2015; 29:1831–1836. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, noninferiority trials. Lancet 2015; 385:2606–2615. Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS 2019; 33:1455–1465. Post FA, Tebas P, Clarke A, Cotte L, Short W, Abram ME, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label Phase 3 study. J Acquir Immune Defic Syndr 2017; 74:180–184. Ibrahim F, Campbell L, Bailey AC, Stockwell S, Waters L, Orkin C, et al. Estimated glomerular filtration rate slopes on tenofovir alafenamide. HIV Med 2020; 21:607–612. Mikula JM, Manion MM, Maldarelli F, Suarez LM, Norman-Wheeler JF, Ober AG, et al. Tenofovir alafenamide as part of a salvage regimen in a patient with multidrug resistant HIV and tenofovir DF-associated renal tubulopathy. Antivir Ther 2016; 21:553–558. Karris MY. Short communication: resolution of tenofovir disoproxil fumarate induced Fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV-1 and hepatitis B coinfected patient. AIDS Res Hum Retroviruses 2017; 33:718–722. Mothobi NZ, Masters J, Marriott DJ. Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient. Ther Adv Infect Dis 2018; 5:91–95. Hamzah L, Williams D, Bailey AC, Jones R, Ibrahim F, Musso CG, et al. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial. HIV Med 2020; 21:198–203. Campbell L, Barbini B, Burling K, Cromarty B, Hamzah L, Johnson M, et al. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2021; 88:214–219. Mazaheri T, Buchanan D, Hung R, Campbell L, Hamzah L, Bramham K, et al. Creatinine and cystatin C-based estimated glomerular filtration rate estimates of kidney function in Black people with HIV on antiretroviral therapy. AIDS 2023; 37:753–758. Hamzah L, Samarawickrama A, Campbell L, Pope M, Burling K, Walker-Bone K, et al. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients. AIDS 2015; 29:1785–1792. Kooij KW, Vogt L, Wit F, van der Valk M, van Zoest RA, Goorhuis A, et al. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis 2017; 216:622–631. Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med 2018; 19:724–733. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6:341–346. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963–972. |
| المشرفين على المادة: | 99YXE507IL (Tenofovir) EL9943AG5J (tenofovir alafenamide) OF5P57N2ZX (Alanine) 0 (Anti-HIV Agents) JAC85A2161 (Adenine) |
| تواريخ الأحداث: | Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240627 |
| رمز التحديث: | 20240627 |
| DOI: | 10.1097/QAD.0000000000003916 |
| PMID: | 38932750 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-5571 |
|---|---|
| DOI: | 10.1097/QAD.0000000000003916 |